Abu Dhabi Launches Life Sciences Cluster to Advance Healthcare Innovation Worldwide, tapping a $25.3 trillion market
16.4.2025 15:30:00 CEST | Business Wire | Press release
Abu Dhabi’s new Health, Endurance, Longevity, and Medicine (HELM) cluster to bolster life sciences ecosystem in Abu Dhabi, cementing the emirate’s position as the leading global hub for biotechnology, MedTech and digital health innovationThe cluster is projected to contribute $25.6 billion to Abu Dhabi’s GDP, unlock 30,000 new jobs, and attract $11.5 billion in investment by 2045
Abu Dhabi has launched the groundbreaking life sciences cluster, reinforcing its position as a global hub for biotechnology, MedTech, and digital health. Developed by the Abu Dhabi Department of Economic Development, Abu Dhabi Investment Office (ADIO) and the Department of Health – Abu Dhabi, the Health, Endurance, Longevity, and Medicine (HELM) cluster is designed to drive healthcare innovation, attract international investment, and deliver lasting benefits to global populations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250416840862/en/
Abu Dhabi Launches Life Sciences Cluster to Advance Healthcare Innovation Worldwide, tapping a $25.3 trillion market (Photo: AETOSWire)
Announced during Abu Dhabi Global Health Week, the HELM cluster will serve as a platform for the research, development, manufacturing and commercialisation of advanced health and life science solutions. From AI-powered diagnostics and pharmaceutical manufacturing to gene therapies and precision medicine, the cluster is poised to enable global companies to transform breakthrough science into scalable and accessible, patient-focused solutions.
With its world-class infrastructure, progressive regulations, and strategic geographic location, Abu Dhabi offers unparalleled access to global markets. The emirate’s multicultural talent base, advanced biomanufacturing facilities, and commitment to innovation make it an ideal launchpad for life sciences companies looking to scale globally.
His Excellency Ahmed Jasim Al Zaabi, Chairman of the Abu Dhabi Department of Economic Development, said: “The Abu Dhabi Health, Endurance, Longevity, and Medicine (HELM) cluster will provide global and local stakeholders with a wide range of benefits, including access to cutting-edge technologies, world-class infrastructure and progressive regulatory frameworks. By creating a globally competitive life sciences hub, we are not only accelerating economic growth and diversification, but we are also ensuring that Abu Dhabi remains at the forefront of developing breakthrough healthcare solutions that will benefit humanity at large.”
Built to meet the rising global demand for advanced healthcare, the cluster is designed to tackle some of the world’s most pressing health challenges, including chronic and non-communicable diseases, which account for over 70% of deaths globally, as well as the healthcare needs of ageing populations. It is tapping growth opportunities in the global healthcare market, which is projected to reach $25.3 trillion (AED93 trillion) by 2045.
His Excellency Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi, said: “The launch of Abu Dhabi’s Health, Endurance, Longevity, and Medicine cluster is a bold leap forward in how the world delivers healthcare. We are not just investing in infrastructure, we’re investing in human potential, in breakthroughs that will redefine longevity, and in solutions that will reach far beyond our borders. This is where innovation meets impact.”
Leveraging an innovation-friendly regulatory framework, Abu Dhabi empowers companies to bring breakthrough technologies to market faster, shaping the future of healthcare at speed and scale. Its AI-powered health system and leadership in precision medicine create an environment where innovation thrives across the entire value chain.
As home to one of the world’s largest national genomics programme, the emirate supports research and development by fostering insights from a uniquely diverse genomic landscape, accelerating innovation and advancing the global shift toward personalised treatments. At the same time, Abu Dhabi is strengthening its role in the global pharmaceutical supply chain, offering reliable infrastructure, strategic connectivity, and long-term partnership opportunities for companies navigating an increasingly complex global landscape.
By 2045, the HELM cluster is expected to contribute $25.6 billion (AED 94 billion) to Abu Dhabi’s GDP, attract $11.5 billion (AED 42 billion) in investment, and create 30,000 high-value jobs, supporting the diversification of the emirate’s economy while enabling long-term global health impact.
The cluster is part of Abu Dhabi’s broader strategy to lead globally in emerging industries. It follows the successful launch of the Smart and Autonomous Vehicle Industries (SAVI) cluster in 2023, which addresses smart urban mobility across air, land, and sea– and the AgriFood Growth and Water Abundance (AGWA) cluster in 2024, which addresses food security and water sustainability challenges.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250416840862/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom